BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37744342)

  • 1. Chimeric RNAs reveal putative neoantigen peptides for developing tumor vaccines for breast cancer.
    Mistretta B; Rankothgedera S; Castillo M; Rao M; Holloway K; Bhardwaj A; El Noafal M; Albarracin C; El-Zein R; Rezaei H; Su X; Akbani R; Shao XM; Czerniecki BJ; Karchin R; Bedrosian I; Gunaratne PH
    Front Immunol; 2023; 14():1188831. PubMed ID: 37744342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
    Shao XM; Bhattacharya R; Huang J; Sivakumar IKA; Tokheim C; Zheng L; Hirsch D; Kaminow B; Omdahl A; Bonsack M; Riemer AB; Velculescu VE; Anagnostou V; Pagel KA; Karchin R
    Cancer Immunol Res; 2020 Mar; 8(3):396-408. PubMed ID: 31871119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
    Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
    BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive mutanome analysis of Lewis lung cancer reveals immunogenic neoantigens for therapeutic vaccines.
    Chen T; Hu R; Wan Y; Sun F; Wang Z; Yue J; Chen J; Han G; Wei G; Dong Z
    Biochem Biophys Res Commun; 2020 May; 525(3):607-613. PubMed ID: 32115148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
    Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent read-through fusion transcripts in breast cancer.
    Varley KE; Gertz J; Roberts BS; Davis NS; Bowling KM; Kirby MK; Nesmith AS; Oliver PG; Grizzle WE; Forero A; Buchsbaum DJ; LoBuglio AF; Myers RM
    Breast Cancer Res Treat; 2014 Jul; 146(2):287-97. PubMed ID: 24929677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines.
    Aguilar-Gurrieri C; Barajas A; Rovirosa C; Ortiz R; Urrea V; de la Iglesia N; Clotet B; Blanco J; Carrillo J
    Cancer Immunol Immunother; 2023 Jul; 72(7):2113-2125. PubMed ID: 36820900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer.
    Kalina JL; Neilson DS; Lin YY; Hamilton PT; Comber AP; Loy EMH; Sahinalp SC; Collins CC; Hach F; Lum JJ
    Clin Cancer Res; 2017 Dec; 23(24):7596-7607. PubMed ID: 28954787
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model.
    Kang J; Lee HJ; Lee J; Hong J; Hong Kim Y; Disis ML; Gim JA; Park KH
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36109084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
    Ha KC; Lalonde E; Li L; Cavallone L; Natrajan R; Lambros MB; Mitsopoulos C; Hakas J; Kozarewa I; Fenwick K; Lord CJ; Ashworth A; Vincent-Salomon A; Basik M; Reis-Filho JS; Majewski J; Foulkes WD
    BMC Med Genomics; 2011 Oct; 4():75. PubMed ID: 22032724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma.
    Zhang Y; Lin Z; Wan Y; Cai H; Deng L; Li R
    Front Immunol; 2019; 10():2472. PubMed ID: 31749795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoantigens as potential vaccines in hepatocellular carcinoma.
    Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Aparicio B; Egea J; Tamayo-Uria I; Hervás-Stubbs S; García-Balduz J; Castro C; Iñarrairaegui M; Tagliamonte M; Mauriello A; Cavalluzzo B; Buonaguro L; Rohrer C; Heim K; Tauber C; Hofmann M; Thimme R; Sangro B; Sarobe P
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193931
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Zhang Z; Zhou C; Tang L; Gong Y; Wei Z; Zhang G; Wang F; Liu Q; Yu J
    Aging (Albany NY); 2020 Jul; 12(14):14633-14648. PubMed ID: 32697765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
    Chen I; Chen MY; Goedegebuure SP; Gillanders WE
    Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.